Inhalation drug delivery is evolving beyond respiratory diseases, unlocking new opportunities for targeted, systemic treatment. Dry powder inhalers (DPIs) offer distinct advantages over liquid formulations, including improved stability, faster absorption, and enhanced patient convenience. However, developing DPIs presents unique challenges, from formulation complexities and device compatibility to regulatory hurdles and scalable manufacturing. Advancements in particle engineering, excipient selection, and analytical methods are driving innovation in this space, while strategic partnerships with experienced CDMOs are helping to accelerate development and commercialization. As interest in inhaled biologics, RNA therapeutics, and vaccine delivery grows, DPI technology is poised to transform drug development and expand treatment possibilities across multiple therapeutic areas.